Davidson Michael H.
SEC CIK 1573785 · EDGAR
BoughtSold
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 16:30 | 2026-09-14 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | P - Purchase | $22.65 | +10.0K | 792.9K | +1% | +$226.5K | |
| D | 2026-03-02 | 2026-03-02 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | S - Sale+OE | $33.25 | -443.7K | 174.1K | -72% | -$14.75M |
| D | 2026-03-02 | 2026-03-02 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | M - OptEx | — | +443.7K | 617.9K | +255% | — |
| DMT | 2026-02-26 | 2026-02-24+ | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | M - OptEx | — | +306.3K | 643.2K | +91% | — |
| DMT | 2026-02-26 | 2026-02-24+ | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | S - Sale+OE | $34.53 | -306.3K | 174.1K | -64% | -$10.58M |
| DT | 2026-01-09 | 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | A - Grant | — | +81.0K | 459.9K | +21% | — |
| DT | 2026-01-09 | 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | S - Sale | — | -11.6K | 378.9K | -3% | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | M - OptEx | $0.00 | +38.4K | 402.7K | +11% | $0 |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | S - Sale+OE | — | -12.3K | 390.4K | -3% | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | A - Grant | $0.00 | +31.0K | 364.3K | +9% | $0 |
| D | 2025-01-07 | 2025-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | A - Grant | — | +123.5K | 123.5K | New | — |
| 2024-08-22 | 2024-08-20 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | P - Purchase | $16.27 | +5,000 | 209.8K | +2% | +$81.3K | |
| D | 2024-08-08 | 2024-08-08 | TENX | TENAX THERAPEUTICS, INC. | Davidson Michael H. | Dir | P - Purchase | — | +2,500 | 2,881 | +656% | — |
| 2024-06-24 | 2024-06-20 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | CEO, Dir | P - Purchase | $17.26 | +5,000 | 204.8K | +3% | +$86.3K | |
| 2022-01-12 | 2022-01-10 | LSTA | LISATA THERAPEUTICS, INC. | Davidson Michael H. | Dir | A - Grant | $0.00 | +65.4K | 209.8K | +45% | $0 |
Purchase Sale Sale after option exercise All abbreviations